河北医科大学学报

• 论著 • 上一篇    下一篇

奈达铂联合 5- 氟尿嘧啶新辅助化疗食管癌手术患者的疗效观察

  

  1. 1.河北省邯郸市中心医院肿瘤内科,河北 邯郸 056001;2.河北省邯郸市中心医院心脏血管外科,河北 邯郸 056001
  • 出版日期:2016-08-25 发布日期:2016-09-01
  • 作者简介:田敬荣( 1979- ),女,河北唐山人,河北省邯郸市中 心医院主治医师,医学学士,从事恶性肿瘤诊治研究。

Clinical study of nedaplatin combined with 5FU in neoadjuvant chemotherapy for esophageal cancer patients#br#

  1. 1.Department of Medical Oncology, the Central Hospital of Handan, Hebei Province, Handan 
    056001, China; 2.Department of Cardiothoracic Surgery, The Central Hospital of
    Handan, Hebei Province, Handan  056001, China
  • Online:2016-08-25 Published:2016-09-01

摘要: [摘要] 目的 观察奈达铂联合 5- 氟尿嘧啶( 5-fluorouracil , 5-FU )新辅助化疗对食管癌手术患者的疗效和安
全性。方法 选取 72 例食管癌患者随机分为治疗组和对照组各 36 例。治疗组术前采用奈达铂联合 5-FU 化疗 2
个周期,化疗结束后 3~4 周进行手术治疗;对照组直接进行手术切除。对比 2 组治疗根治性切除率、术后并发症
发生率以及术后 3 年生存率。结果 2 组均顺利完成手术,治疗组手术根治性切除率为 88.9% ,术后并发症发生率
为 41.7% ,术后 3 年生存率为 60.0% ;对照组则分别为 69.4% 、 36.1% 、 34.3% 。 2 组根治性切除率及术后 3 年的
生存率差异有统计学意义,术后并发症发病率差异无统计学意义。结论 奈达铂联合 5-FU 新辅助化疗可显著提高
食管癌根治性切除率,提高患者的生存率,不增加并发症的发生率,值得临床上推广使用

关键词: 食管肿瘤, 氟尿嘧啶, 放化疗, 辅助

Abstract: [ Abstract ] Objective Todetecttheclinicalefficacyandsafetyofneo-adjuvantchemotherapy
withnedaplatinand5-fluorouracil ( 5-FU ) forthepatientswithesophagealcancer.Methods A
totalof72patientswithesophagealcancerrandomlydividedintotreatmentgroup ( 36cases ) and
controlgroup ( 36cases ) .Treatmentgroupreceivedneo-adjuvantchemotherapywithnedaplatin
and5-FUfor2cyclesandunderwentoperation3-4weeksafterchemotherapy.Thepatientsof
controlgroup weretreated with operationalone.Theradicalresectionrate , postoperative
complicationrateandthree-yearsurvivalratewerecomparedbetweenthetwogroups.Results
Thepatientsoftwogroupsweresuccessfullycompletedtheoperation.Theradicalresectionrate ,
postoperativecomplicationrate , three-yearsurvivalrateofthetreatmentgroupwere88.9% ,
41.7% , 60.0% andthoseofcontrolgroup were69.4% , 36.1% , 34.3% , respectively.The
radicalresectionrateandthree-yearssurvivalratebetweenthetwogroupsweresignificantly
different , buttherewasnosignificantdifferenceinpostoperativecomplicationrate.Conclusion
Nedaplatininneo-adjuvantchemotherapyforesophagealcancercouldsignificantlyincreaseradical
resection rate and three-year survival rate and presented no negative influence on the postoperativecomplicationrate , whichisworthyofclinicalapplication.

Key words: esophagealneoplasms , fluorouracil , chemoradiotherapy, adjuvant